[{"from": "human", "value": "Describe this molecule. [C][N][C][=C][C][=C][Branch1][N][C][=Branch1][Branch2][=C][C][Ring1][=Branch1][=N][Ring1][=Branch2][F][C][Branch2][Ring1][=C][C][=N][N][=C][N][Ring1][Branch1][N][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=C][N][Branch1][Branch1][N][=C][Ring1][Branch1][C][C][C][Ring1][Ring1][Branch1][C][F][F]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) with potential antineoplastic activity. Upon administration, vebreltinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."}]